Pediatric cancer: Understanding the unique characteristics of childhood cancers

Pediatric cancer: A rare disease with unique characteristics

Why are childhood cancers different from adult cancers?

Although they share the same name, childhood cancers and adult cancers often differ significantly from a biological perspective.

In adults, cancers frequently result from the gradual accumulation of genetic alterations influenced by aging, environmental factors, or risk factors such as smoking, alcohol consumption, and exposure to carcinogenic substances. In contrast, most pediatric cancers arise from abnormalities that occur during a child’s development, often with no clearly identifiable cause.

Environmental factors and lifestyle habits generally play a much smaller role in childhood cancers. According to the WHO and the National Cancer Institute (NCI), only 8% to 10% of pediatric cancers are associated with an inherited genetic predisposition.

These biological differences explain why pediatric cancers require dedicated diagnostic, therapeutic, and research approaches.

What are the most common types of childhood cancer?

Unlike adults, for whom breast, lung, prostate, and colorectal cancers are the most common, pediatric cancers primarily affect developing tissues.

The main types of childhood cancer include:

• Leukemias, which account for approximately one-third of all pediatric cancers;
• Brain and central nervous system tumors;
• Lymphomas;
• Neuroblastomas, which develop from immature nerve cells;
• Wilms tumors, which primarily affect the kidneys;
• Bone and soft tissue sarcomas, such as osteosarcoma and Ewing sarcoma;
• Retinoblastomas, rare cancers of the retina.

This diversity illustrates the complexity of pediatric oncology and highlights the need for specialized expertise for each tumor type.

The importance of early diagnosis in children

Why is diagnosis often challenging?

One of the greatest challenges in pediatric cancer is achieving an early diagnosis.

Initial symptoms may be subtle and easily mistaken for common childhood illnesses. Unusual fatigue, persistent fever, bone pain, recurring headaches, or unexplained weight loss can be associated with a wide range of benign conditions.

The rarity of pediatric cancers also makes them more difficult to recognize. Healthcare professionals may encounter relatively few cases throughout their careers, which can sometimes delay referral for specialized investigations.

The consequences of delayed diagnosis

As with many oncological diseases, early diagnosis significantly improves treatment outcomes.

When a tumor is diagnosed at a later stage, the disease may have progressed further, requiring more intensive treatments and increasing the risk of complications. Globally, diagnostic delays remain one of the major factors contributing to disparities in survival rates between countries.

Raising awareness among families, pediatricians, and healthcare professionals about warning signs is therefore essential to improving outcomes for young patients.

Why is there no universal screening program?

Unlike certain adult cancers, such as breast cancer or colorectal cancer, there is currently no widespread screening program for pediatric cancers.

Several factors explain this:

• Their low incidence within the general population;
• The lack of sufficiently reliable screening tests for large-scale use;
• The broad diversity of childhood cancers.

In specific situations, when a genetic predisposition has been identified within a family, targeted surveillance may nevertheless be recommended.

How are childhood cancers treated today?

Standard treatment options

Treatment for pediatric cancer depends on several factors, including the type of cancer, disease stage, the child’s age, and the biological characteristics of the tumor.

The main treatment approaches include:

• Chemotherapy;
• Surgery;
• Radiation therapy;
• Hematopoietic stem cell transplantation in selected indications.

Care is delivered by multidisciplinary teams involving pediatric oncologists, surgeons, radiation oncologists, biologists, psychologists, specialized nurses, and other healthcare professionals.

This comprehensive approach is essential to address not only the disease itself but also the child’s physical, cognitive, and emotional development.

Continually improving outcomes

Pediatric oncology is one of the fields that has seen some of the most remarkable advances in modern medicine.

While survival prospects were limited just a few decades ago, therapeutic innovations and improved treatment protocols have transformed the landscape. Today, more than 80% of children diagnosed with cancer can be cured in countries with access to specialized healthcare infrastructures.

These achievements are largely the result of advances generated through clinical research and decades of patient participation in pediatric clinical trials.

The challenge of long-term side effects

Improving survival rates remains a top priority, but it is no longer the sole objective.

Cancer treatments administered during childhood can sometimes lead to late effects that emerge years after treatment has ended.

These long-term consequences may affect:

• Growth and development;
• Fertility;
• Cognitive function;
• Cardiovascular health;
• Psychological well-being and quality of life.

As a result, childhood cancer survivors typically benefit from long-term medical follow-up to identify and manage potential complications as early as possible.

Pediatric clinical research: Meeting the challenges of developing tomorrow’s treatments

Why are pediatric clinical trials particularly complex?

Developing new treatments for children presents major scientific and operational challenges.

Unlike adult cancers, pediatric cancers remain relatively rare. The limited number of eligible patients can make recruitment difficult, while the heterogeneity of diseases often requires highly specific study protocols.

Ethical requirements are also especially stringent because patients are minors. Every study must maintain a careful balance between therapeutic innovation, patient safety, and potential benefit.

In this context, international research networks play a critical role in sharing expertise and enabling patient recruitment across multiple countries.

The evolution of the regulatory landscape for children

Over recent years, health authorities have strengthened requirements aimed at better integrating pediatric populations into drug development programs.

These developments encourage pharmaceutical companies to consider children’s needs earlier in their clinical development strategies and support the creation of programs specifically designed for pediatric diseases.

This momentum relies on close collaboration between industry stakeholders, academic institutions, patient advocacy groups, regulatory authorities, and specialized clinical research partners.

Why is participation in clinical trials essential?

A significant share of today’s progress in pediatric oncology is a direct result of clinical research.

Clinical trials make it possible to:

• Evaluate the safety and efficacy of new treatments;
• Improve existing standards of care;
• Provide patients with access to innovative therapies;
• Generate robust scientific data for future generations.

Every study contributes to advancing knowledge and improving care for children living with cancer.

Innovations shaping the future of pediatric oncology

Clinical research plays a pivotal role in developing new therapeutic approaches that improve outcomes while reducing treatment-related toxicity. Given the rarity of pediatric cancers and their biological differences from adult cancers, innovation remains essential to addressing the unmet needs of young patients.

Targeted therapies

Advances in molecular biology have significantly improved our understanding of the mechanisms underlying certain pediatric cancers. By identifying specific genetic alterations, researchers are developing targeted therapies capable of acting on precise abnormalities involved in tumor growth.

These approaches, evaluated through dedicated clinical trials, pave the way for more personalized treatments that may be less toxic than conventional therapies. Tumor genomic profiling is becoming increasingly important in identifying patients who may benefit from these innovative therapeutic options.

The rise of immunotherapy

Among the most promising innovations in pediatric oncology is immunotherapy. This approach harnesses the patient’s own immune system to recognize and destroy cancer cells more effectively.

Already incorporated into certain indications, particularly for specific pediatric leukemias, immunotherapy continues to be explored in numerous research programs aimed at expanding its use to other tumor types. Results observed in several clinical trials are fueling hope for treatments that are both more effective and better tolerated.

Emerging innovative approaches

Beyond targeted therapies and immunotherapy, clinical research is exploring a wide range of next-generation strategies:

• Cell therapies;
• Bispecific and multispecific antibodies;
• Antibody-drug conjugates (ADCs);
• Therapeutic cancer vaccines;
• Treatments targeting novel molecular pathways.

These innovations require particularly rigorous clinical development programs to evaluate their safety, efficacy, and potential role within future pediatric standards of care.